Clinical Trial Update: A Proof of Concept Study With Rituximab in Patients With CIDP Not Responding to Conventional Immune Therapy [Phase 2]

View source ↗

Summary

A Phase 2 proof-of-concept trial evaluating rituximab in CIDP patients who did not respond to conventional immune therapy. Overall status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Istituto Clinico Humanitas | Conditions: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Phase 2 | Status: UNKNOWN